Melatonin–selenium nanoformulation: a promising therapeutic strategy against Ehrlich ascites carcinoma

Hanaa M. Morad, A. F. Abdel-Aziz, Mai M. Madkour · 2026

Read Melatonin–selenium nanoformulation: a promising therapeutic strategy against Ehrlich ascites carcinoma by Hanaa M. Morad, A. F. Abdel-Aziz, Mai M. Madkour (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13212612.txt.

Description

Hanaa M. Morad, A. F. Abdel-Aziz, and Mai M. Madkour report in 2026 on tiny particles combining melatonin with selenium as a possible cancer treatment. Their test system was a fast-growing mouse tumour model widely used for early screening of anticancer compounds.

In treated animals, the combined particles slowed tumour growth and strengthened antioxidant defences better than either ingredient alone. A key inflammatory signal fell, and tumour cells showed more programmed death, with a growth marker reduced and cell division stalled at an early phase. The results are early and animal-based, yet they support testing this multi-target pairing further before any claims about human use.

Catalog record

CREATORHanaa M. Morad, A. F. Abdel-Aziz, Mai M. Madkour
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE79 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13212612

Browse the full library · About the Tower of Babel